Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: A three-year retrospective cohort study

International Journal of Artificial Organs

Volumn 34, Issue 7, 2011, Pages 571-576

  Maruyama, Yukio ^a   Yoshida, Hiraku ^a   Uchino, Shigehiko ^a   Yokoyama, Keitaro ^a   Yamamoto, Hiroyasu ^a   Takinami, Masanori ^a   Hosoya, Tatsuo ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Activated partial thromboplastin time; Acute kidney injury; Bleeding complications; Continuous venovenous hemodialysis; Filter survival; Nafamostat mesilate

Indexed keywords

AMINO ACIDS; ANALYSIS OF VARIANCE (ANOVA); BANDPASS FILTERS; DIALYSIS; ENZYME INHIBITION; PATIENT TREATMENT;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACUTE KIDNEY INJURY; BLEEDING COMPLICATION; BLEEDINGS; COHORT STUDIES; CONTINUOUS VENOVENOUS HEMODIALYSIS; FILTER SURVIVAL; HAEMODIALYSIS; NAFAMOSTAT MESILATE; RENAL REPLACEMENT THERAPIES;

HEMODIALYZERS;

CREATININE; NAFAMSTAT MESILATE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANALYSIS OF VARIANCE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; FEMALE; FILTER; HEMATOCRIT; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; SAFETY; STATISTICAL SIGNIFICANCE; ULTRAFILTRATION;

EID: 79961087823     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/IJAO.2011.8535     Document Type: Article

References (22)

1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818. Medline. doi:10.1001/jama.294.7.813
2. Oudemans-van Straaten HM, Wester J P, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32(2):188-202. Medline. doi:10.1007/ s00134-005-0044-y
3. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563-1570. Medline. doi:10.1007/s00134-007-0754-4
4. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofltration and continuous hemodiafltration. Contrib Nephrol. 1991;93:215-217.
5. Le Gall JR, Lemeshow S, Saulnier F. A new Simplifed Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957-2963. Medline. doi:10.1001/jama.270.24.2957
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classifcation system. Crit Care Med. 1985;13(10):818-829. Medline. doi:10.1097/00003246-198510000-00009
7. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):377-381. Medline. doi:10.1056/NEJM199402103300601
8. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between flter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7(1):145-150.
9. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67(6):2361-2367. Medline. doi:10.1111/j.1523-1755.2005.00342.x
10. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260-265. Medline. doi:10.1007/s00134-003-2047-x
11. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santa-maria JD. A controlled trial of low-molecular-weight hepa-rin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with fltration. Crit Care Med. 1999;27(10):2224-2228. Medline. doi:10.1097/00003246-199910000-00026
12. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous venovenous hemofltration without antico-agulation. ASAIO J. 2004;50(1):76-80. doi:10.1097/01. MAT.0000104822.30759.A7
13. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofltration. Crit Care Med. 2009;37(2):545-552. Medline. doi:10.1097/CCM.0b013e3181953c5e
14. Joannidis M, Kountchev J, Rauchenzauner M, et al. Enox-aparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofltration: a randomized controlled crossover study. Intensive Care Med. 2007;33(9):1571-1579. Medline. doi:10.1007/s00134-007-0719-7
15. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15(3):164-168.
16. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3):203-227.
17. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haema-tol. 2006;133(3):259-269. Medline. doi:10.1111/j.1365-2141.2006.06018.x
18. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26(Suppl 2):24-38.
19. Fiaccadori E, Maggiore U, Rotelli C, et al. Continuous hae-mofltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med. 2002;28(5):586-593. Medline. doi:10.1007/s00134-002-1249-y
20. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacoki-netics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450-2455. Medline. doi:10.1097/01.CCM.0000084871.76568.E6
21. Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment ef-fcacy and excellent control of the acid-base status. Crit Care Med. 2009;37(6):2018-2024. Medline. doi:10.1097/ CCM.0b013e3181a00a92
22. Mariano F, Tedeschi L, Morselli M, et al. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemo-diafltration in severe septic shock burn patients. Intensive Care Med. 2010;36(10):1735-1743. Medline. doi:10.1007/ s00134-010-1909-2